Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Website: theseusrx.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 33.2% (LTM)

Entry Point: Share price is 91.7% higher than minimum and 79.8% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: THRX
Share price, USD:  (0.0%)4.065
year average price 4.79  


year start price 10.24 2023-04-29

max close price 11.82 2023-05-04

min close price 2.12 2023-11-10

current price 4.07 2024-04-27
Common stocks: 38 490 104

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 156
Net Debt ($m): -142
EV (Enterprise Value): 14
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-12-29Zacks Investment Research

Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?

2023-11-27Zacks Investment Research

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

2023-09-29Seeking Alpha

Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure

2023-08-11Zacks Investment Research

Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)

2023-07-18Zacks Investment Research

After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)

2023-07-17Zacks Investment Research

Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study

2023-07-14InvestorPlace

Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?

2023-07-13Market Watch

Theseus Pharmaceuticals stock plummets after cancer drug development stopped

2023-04-04Zacks Investment Research

Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol THRX THRX THRX THRX THRX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-17 2023-08-10 2023-05-11 2023-03-09 2022-11-03
acceptedDate 2023-11-17 16:01:52 2023-08-10 07:06:16 2023-05-11 07:12:20 2023-03-09 07:15:36 2022-11-03 07:05:34
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0
costOfRevenue 22 507 158 709 0 0 0
grossProfit -22 507 -158 709 0 0 0
grossProfitRatio 0 0 0 0 0
researchAndDevelopmentExpenses 12M 13M 12M 10M 11M
generalAndAdministrativeExpenses 5M 5M 5M 5M 5M
sellingAndMarketingExpenses 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 5M 5M 5M
otherExpenses 3M 3M 2M 2M 0
operatingExpenses 16M 18M 17M 15M 16M
costAndExpenses 16M 18M 17M 15M 16M
interestIncome 3M 3M 0 0 0
interestExpense 0 0 -2M 2M -1M
depreciationAndAmortization 22 000 21 000 20 000 20 000 18 000
ebitda -16M -18M -17M -15M -16M
ebitdaratio 0 0 0 0 0
operatingIncome -16M -18M -17M -15M -16M
operatingIncomeRatio 0 0 0 0 0
totalOtherIncomeExpensesNet 3M 3M 2M 2M 1M
incomeBeforeTax -14M -15M -15M -14M -15M
incomeBeforeTaxRatio 0 0 0 0 0
incomeTaxExpense -22 000 0 -2M 2M -1M
netIncome -14M -15M -12M -15M -14M
netIncomeRatio 0 0 0 0 0
eps -0.310 -0.340 -0.290 -0.400 -0.350
epsdiluted -0.310 -0.340 -0.290 -0.400 -0.350
weightedAverageShsOut 44M 44M 42M 39M 39M
weightedAverageShsOutDil 44M 44M 42M 39M 39M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol THRX THRX THRX THRX THRX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-17 2023-08-10 2023-05-11 2023-03-09 2022-11-03
acceptedDate 2023-11-17 16:01:52 2023-08-10 07:06:16 2023-05-11 07:12:20 2023-03-09 07:15:36 2022-11-03 07:05:34
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 47M 47M 110M 95M 116M
shortTermInvestments 158M 161M 127M 103M 97M
cashAndShortTermInvestments 205M 208M 237M 198M 212M
netReceivables 0 0 0 0 0
inventory 0 0 0 0 0
otherCurrentAssets 4M 6M 6M 4M 3M
totalCurrentAssets 210M 214M 237M 198M 215M
propertyPlantEquipmentNet 4M 4M 5M 5M 5M
goodwill 0 0 0 0 0
intangibleAssets 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0
longTermInvestments 20M 26M 7M 14M 9M
taxAssets 0 0 0 0 0
otherNonCurrentAssets 399 000 794 000 7M 6M 2M
totalNonCurrentAssets 25M 31M 19M 24M 15M
otherAssets 0 0 0 0 0
totalAssets 235M 245M 256M 222M 230M
accountPayables 1M 2M 2M 5M 2M
shortTermDebt 759 000 754 000 748 000 743 000 779 000
taxPayables 0 0 0 0 0
deferredRevenue 5M 4M 0 0 0
otherCurrentLiabilities 349 000 349 000 4M 5M 5M
totalCurrentLiabilities 7M 8M 7M 11M 8M
longTermDebt 3M 3M 3M 3M 3M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 205 000 292 000 379 000 466 000 1M
totalNonCurrentLiabilities 3M 3M 4M 4M 4M
otherLiabilities 0 0.000 0 0 0
capitalLeaseObligations 4M 4M 4M 4M 4M
totalLiabilities 10M 11M 10M 15M 12M
preferredStock 0 0 0 0 0
commonStock 4000.000 4000.000 4000.000 4000.000 4000.000
retainedEarnings -155M -142M -127M -112M -98M
accumulatedOtherComprehensiveIncomeLoss -345 000 -561 000 -159 000 -386 000 -550 000
othertotalStockholdersEquity 380M 376M 372M 320M 318M
totalStockholdersEquity 225M 234M 245M 208M 219M
totalEquity 225M 234M 245M 208M 219M
totalLiabilitiesAndStockholdersEquity 235M 245M 256M 222M 230M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 235M 245M 256M 222M 230M
totalInvestments 179M 187M 134M 117M 105M
totalDebt 4M 4M 4M 4M 4M
netDebt -43M -44M -106M -91M -111M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol THRX THRX THRX THRX THRX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-17 2023-08-10 2023-05-11 2023-03-09 2022-11-03
acceptedDate 2023-11-17 16:01:52 2023-08-10 07:06:16 2023-05-11 07:12:20 2023-03-09 07:15:36 2022-11-03 07:05:34
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
netIncome -14M -15M -15M -14M -15M
depreciationAndAmortization 22 000 21 000 20 000 20 000 18 000
deferredIncomeTax -2M -1M 0 0 0
stockBasedCompensation 4M 4M 3M 2M 4M
changeInWorkingCapital 356 000 2M -6M 2M 3M
accountsReceivables 0 0 0 0 0
inventory 0 0 0 0 0
accountsPayables -1M 191 000 -3M 3M 314 000
otherWorkingCapital 1M 2M 3M -1M 2M
otherNonCashItems 194 000 53 000 -598 000 -361 000 252 000
netCashProvidedByOperatingActivities -11M -10M -19M -10M -7M
investmentsInPropertyPlantAndEquipment -50 000 -11 000 11 000 -11 000 -63 000
acquisitionsNet 0 51 928 0 167M 0
purchasesOfInvestments -10M -83M -57M -36M -62M
salesMaturitiesOfInvestments 20M 31M 41M 25M 0
otherInvestingActivites 0 -51 928 -11 000 -167M 50M
netCashUsedForInvestingActivites 10M -52M -16M -11M -12M
debtRepayment 0 0 0 0 0
commonStockIssued 0 142 000 49M 0 0
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 0 0 48 000 112 000 0
netCashUsedProvidedByFinancingActivities 0 142 000 49M 112 000 0
effectOfForexChangesOnCash 0 0 0 0 0
netChangeInCash -949 000 -62M 15M -21M -20M
cashAtEndOfPeriod 47M 48M 110M 95M 116M
cashAtBeginningOfPeriod 48M 110M 95M 116M 135M
operatingCashFlow -11M -10M -19M -10M -7M
capitalExpenditure -50 000 -11 000 11 000 -11 000 -63 000
freeCashFlow -11M -10M -19M -10M -7M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-14 13:30 ET
Theseus Pharmaceuticals Announces Closing of Tender Offer
2024-01-30 13:00 ET
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
2023-12-22 11:30 ET
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
2023-11-27 11:30 ET
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
2023-11-13 21:05 ET
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
2023-11-07 21:05 ET
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
2023-08-10 11:00 ET
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
2023-07-13 20:05 ET
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
2023-05-31 11:00 ET
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
2023-05-25 21:01 ET
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
2023-05-11 11:00 ET
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
2023-04-26 14:05 ET
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
2023-04-11 11:00 ET
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-03-28 11:00 ET
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
2023-03-09 12:00 ET
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-07 12:00 ET
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
2023-01-05 12:00 ET
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
2022-11-03 11:00 ET
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results
2022-10-26 11:00 ET
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
2022-10-19 11:00 ET
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
2022-10-03 11:00 ET
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
2022-09-06 12:30 ET
Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
2022-08-11 11:00 ET
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results
2022-08-03 12:30 ET
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
2022-05-19 12:30 ET
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-05-18 12:30 ET
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
2022-05-12 11:00 ET
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
2022-04-08 17:00 ET
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
2022-04-05 12:30 ET
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
2022-03-10 12:00 ET
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-08 22:01 ET
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
2022-02-09 12:30 ET
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
2022-02-02 12:30 ET
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
2022-01-10 12:00 ET
Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
2021-11-15 12:00 ET
Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
2021-11-10 12:00 ET
Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference
2021-10-07 02:20 ET
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2023-11-17 16:01 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q3
SEC form 10
2023-11-17 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q3
SEC form 8
2023-11-13 16:06 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q3
SEC form 10
2023-08-10 07:06 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-08-10 07:05 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-07-13 16:08 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q2
SEC form 8
2023-07-13 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q2
SEC form 10
2023-05-11 07:12 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 6
2023-05-11 07:09 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 6
2023-04-26 09:00 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-04-14 09:00 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q1
SEC form 10
2023-03-09 07:15 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-03-09 07:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 8
2023-03-09 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-01-05 07:02 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q4
SEC form 8
2023-01-05 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2022-11-03 07:05 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-11-03 07:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-10-19 07:16 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q3
SEC form 6
2022-10-19 07:15 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q3
SEC form 10
2022-08-11 07:18 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-08-11 07:15 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-06-13 16:39 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-05-18 16:24 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-05-18 16:22 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-12 07:21 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-05-12 07:15 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-04-25 16:30 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-03-10 07:23 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-10 07:15 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2022-03-10 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-01-10 07:16 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2021-11-15 07:36 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-11-15 07:30 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-27 16:14 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:01 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:01 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:01 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3